MARKET

IRON

IRON

Disc Medicine Inc
NASDAQ
77.05
-1.58
-2.01%
Opening 14:23 01/06 EST
OPEN
77.58
PREV CLOSE
78.63
HIGH
78.39
LOW
76.24
VOLUME
404.59K
TURNOVER
--
52 WEEK HIGH
99.50
52 WEEK LOW
30.82
MARKET CAP
2.91B
P/E (TTM)
-14.3914
1D
5D
1M
3M
1Y
5Y
1D
Disc Medicine Chief Legal Officer Rahul Khara Reports Disposal of Common Shares
Reuters · 18h ago
Disc Medicine: RALLY-MF Data Validates Pipeline Optionality
Seeking Alpha · 1d ago
Weekly Report: what happened at IRON last week (1229-0102)?
Weekly Report · 1d ago
Weekly Report: what happened at IRON last week (1222-1226)?
Weekly Report · 12/29/2025 09:10
Seadrill, Vestis, Mastercraft Boat, and More Stocks See Action From Activist Investors
Barron‘s · 12/26/2025 22:14
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Disc Medicine (IRON) and Ascendis Pharma (ASND)
TipRanks · 12/22/2025 14:00
Weekly Report: what happened at IRON last week (1215-1219)?
Weekly Report · 12/22/2025 09:10
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Disc Medicine (IRON) and Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks · 12/22/2025 02:20
More
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Webull offers Disc Medicine Inc stock information, including NASDAQ: IRON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRON stock methods without spending real money on the virtual paper trading platform.